Mycobacterial and Other Serious Infections in Patients Receiving Anti–Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network

This publication has 10 references indexed in Scilit:

• Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy
  Nature Clinical Practice Rheumatology, 2007
• B Cells Moderate Inflammatory Progression and Enhance Bacterial Containment upon Pulmonary Challenge withMycobacterium tuberculosis
  The Journal of Immunology, 2007
• An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
  American Journal of Respiratory and Critical Care Medicine, 2007
• Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
  Arthritis & Rheumatism, 2006
• Glucocorticoid use, other associated factors, and the risk of tuberculosis
  Arthritis Care & Research, 2006
• Tuberculosis associated with therapy against tumor necrosis factor α
  Arthritis & Rheumatism, 2005
• Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
  Arthritis & Rheumatism, 2005
• Human tuberculous granulomas induce peripheral lymphoid follicle‐like structures to orchestrate local host defence in the lung
  The Journal of Pathology, 2004
• Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
  Clinical Infectious Diseases, 2004
• A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis
  AIDS, 2004